Printer Friendly

Cantor sees uniQure as next gene therapy buyout, ups price target to $81.

Cantor Fitzgerald analyst Elemer Piros raised his price target for uniQure (QURE) to $81 from $68 after Roche (RHHBY) acquired Spark Therapeutics (ONCE) for $4.8B. The stock in premarket trading is up 18%, or $7.38, to $48.98. The analyst sees a "number of reasons" why uniQure could be the next gene therapy company to be acquired, "potentially by one of the bidders involved in the Spark sale." uniQure has an established hemophilia pipeline, its pipeline mimics Spark's in many ways, and is a leader in manufacturing, Piros tells investors in a research note. He reiterates an Overweight rating on uniQure.

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Feb 25, 2019
Words:103
Previous Article:NanoLock, Micron collaborate to offer flash-to-cloud management solution.
Next Article:First Majestic reports results from 2018 exploration program at Ermitano project.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters